Cowen and Company Reaffirms “Buy” Rating for Heron Therapeutics, Inc. (HRTX)

Cowen and Company reaffirmed their buy rating on shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) in a report released on Friday. The firm currently has a $40.00 price target on the biotechnology company’s stock.

“Yesterday Heron released positive Ph 2 abdominoplasty data for HTX-011.”,” Cowen and Company’s analyst wrote.

HRTX has been the subject of a number of other reports. Zacks Investment Research upgraded Heron Therapeutics from a sell rating to a hold rating in a research note on Tuesday, October 11th. JMP Securities restated a buy rating on shares of Heron Therapeutics in a research note on Wednesday, November 9th. Jefferies Group cut their price target on Heron Therapeutics from $46.00 to $40.00 and set a buy rating for the company in a research note on Monday, October 3rd. Aegis started coverage on Heron Therapeutics in a research note on Wednesday, October 26th. They set a buy rating and a $41.00 price target for the company. Finally, Brean Capital started coverage on Heron Therapeutics in a research note on Tuesday, October 4th. They set a buy rating and a $41.00 price target for the company. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. Heron Therapeutics has an average rating of Buy and a consensus price target of $37.75.

Heron Therapeutics (NASDAQ:HRTX) traded down 6.30% on Friday, hitting $12.65. 475,071 shares of the company traded hands. Heron Therapeutics has a 1-year low of $12.30 and a 1-year high of $25.84. The firm’s 50 day moving average price is $14.54 and its 200 day moving average price is $17.06.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Tuesday, November 8th. The biotechnology company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($1.17) by $0.07. Equities research analysts predict that Heron Therapeutics will post ($4.51) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Community Financial News and is the propert of of Community Financial News. If you are accessing this report on another domain, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be read at https://www.com-unik.info/2017/01/11/cowen-and-company-reaffirms-buy-rating-for-heron-therapeutics-inc-hrtx.html.

Several hedge funds have recently modified their holdings of the company. RTW Investments LLC purchased a new stake in shares of Heron Therapeutics during the third quarter valued at about $6,664,000. Candriam Luxembourg S.C.A. purchased a new stake in shares of Heron Therapeutics during the third quarter valued at about $1,034,000. Lombard Odier Asset Management USA Corp purchased a new stake in shares of Heron Therapeutics during the third quarter valued at about $3,015,000. Baker BROS. Advisors LP purchased a new stake in shares of Heron Therapeutics during the third quarter valued at about $49,230,000. Finally, Highbridge Capital Management LLC purchased a new stake in shares of Heron Therapeutics during the third quarter valued at about $266,000.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

5 Day Chart for NASDAQ:HRTX

What are top analysts saying about Heron Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Heron Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit